EMA Validates Pfizer-Valneva Lyme Disease Vaccine Marketing Authorization Application

The European Medicines Agency validated the marketing authorization application for the Lyme disease vaccine candidate from Pfizer PFE and Valneva on August 14 . Validation is a procedural milestone confirming the filing is complete enough to enter formal scientific review. It is not an approval decision and carries no efficacy judgment.

The candidate, PF-07307405, also known as VLA15, is a six-valent vaccine targeting the outer surface protein A of the Borrelia strains responsible for Lyme disease in North America and Europe. There is no licensed human Lyme vaccine on either continent today, so the addressable population is defined by exposure rather than by displacing an incumbent product.

The filing rests on the phase 3 VALOR trial, which read out in March 2026 with 73.2% efficacy on the primary endpoint one month after the fourth dose in participants aged five and older . A US submission has not been confirmed as filed, though Pfizer has stated its intent to submit a BLA during 2026 .

The economics are asymmetric between the two partners. For Pfizer this is one candidate inside a large portfolio; for Valneva it is a company-defining asset, which is why Valneva shares traded to their highest level since May on the news while the move in Pfizer was negligible . What to watch is the EMA review clock and confirmation that the US filing has actually gone in.

Related Stocks

• PFE